Inventor · disambiguated record
David Bechard
Also filed as: BECHARD DAVID · BÉCHARD DAVID
9 granted patents·12 pending applications·14 citations·filing 2001–2023
83Inventor score
Top patents by PatentIndex Score
21 records- 0187US10899816B2IL-15 and IL-15Rα sushi domain based immunocytokinesCYTUNE PHARMA·Filed 2018·Granted Jan 26, 2021·4 cites·5 claims
- 0286US10626155B2IL-15 and IL-15R\alpha sushi domain based immunocytokinesCYTUNE PHARMA·Filed 2016·Granted Apr 21, 2020·4 cites·8 claims
- 0379US2024083963A1Il-15 and il-15r\alpha sushi domain based immunocytokinesCYTUNE PHARMA·Filed 2023·Application pending·0 cites
- 0471US11273204B2IL-15 and IL-15RAPLHA sushi domain based immunocytokinesCYTUNE PHARMA·Filed 2014·Granted Mar 15, 2022·2 cites·7 claims
- 0571US10808022B2IL-15/IL-15Ralpha based conjugates purification methodCYTUNE PHARMA·Filed 2015·Granted Oct 20, 2020·1 cites·10 claims
- 0670US11753454B2IL-15 and IL-15R\alpha sushi domain based immunocytokinesCYTUNE PHARMA·Filed 2020·Granted Sep 12, 2023·0 cites·11 claims
- 0765US11401312B2Cytokine derived treatment with reduced vascular leak syndromeCYTUNE PHARMA·Filed 2014·Granted Aug 2, 2022·1 cites·28 claims
- 0865US7473564B2Kit and method for detecting the ESM-1 proteinPASTEUR INSTITUT·Filed 2001·Granted Jan 6, 2009·2 cites·17 claims
- 0960US12060407B2IL-15/IL-15Ralpha based conjugates purification methodCYTUNE PHARMA·Filed 2020·Granted Aug 13, 2024·0 cites·7 claims
- 1059US2022193199A1Il-15 and il-15ralpha sushi domain based modulokinesCYTUNE PHARMA·Filed 2022·Application pending·0 cites
- 1159US2022168395A1Combined pharmaceutical compositionCYTUNE PHARMA·Filed 2022·Application pending·0 cites
- 1259US2024350589A1Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancerCYTUNE PHARMA·Filed 2022·Application pending·0 cites
- 1359US2022202904A1Combined pharmaceutical compositionCYTUNE PHARMA·Filed 2022·Application pending·0 cites
- 1458US2024294594A1Interleukin-15 based immunocytokinesCYTUNE PHARMA·Filed 2022·Application pending·0 cites
- 1557US2023183306A1Cytokine derived treatment with reduced vascular leak syndromeCYTUNE PHARMA·Filed 2022·Application pending·0 cites
- 1655US2023398185A1Il-2/il-15r-beta-gamma agonist for treating non-melanoma skin cancerCYTUNE PHARMA·Filed 2021·Application pending·0 cites
- 1755US2023390361A1Il-2/il-15r-beta-gamma agonist for treating squamous cell carcinomaCYTUNE PHARMA·Filed 2021·Application pending·0 cites
- 1852US2015152188A1AN IL-15 AND IL-15R\alpha SUSHI DOMAIN BASED IMMUNOCYTOKINESCYTUNE·Filed 2012·Application pending·0 cites
- 1947US2022241375A1Il-2/il-15r beta gamma agonist dosing regimens for treating cancer or infectious diseasesCYTUNE PHARMA·Filed 2020·Application pending·0 cites
- 2045US2016184399A1Combined pharmaceutical compositionCYTUNE PHARMA·Filed 2014·Application pending·0 cites
- 2139US7306797B2Use of a compound antagonist of ESM-1 protein for producing a medicine for treating cancerPASTEUR INSTITUT·Filed 2001·Granted Dec 11, 2007·0 cites·1 claims
Join the waitlist — get patent alerts
Get an alert when David Bechard files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →